QOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon® in Korea

Bayer

Status: Withdrawn

Conditions: Multiple Sclerosis, Relapsing-Remitting

Treatments: Drug: Interferon beta 1-b (Betaferon/Betaseron, BAY86-5046)

Study type: Observational

Funder types: Industry

Identifiers

NCT01071694

15110

Qolbet (Other Identifier)

BF1010KR (Other Identifier)

Details and patient eligibility

About

This study is to describe the quality of life of Korean patients with early relapsing-remitting multiple sclerosis during the initial 1 year of treatment with Betaferon with several validated questionnaires.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Relapsing-remitting MS (RRMS) patients within the first two years after diagnosis according to Poser or McDonald criteria, starting Betaferon treatment, including patients switching from other DMDs
• Patients who signed informed consent form

Exclusion criteria

• Age lower than 18

Trial design

0 participants in 1 patient group

Group 1

Treatment:

Drug: Interferon beta 1-b (Betaferon/Betaseron, BAY86-5046)